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Abstract BubR1 is a key component of the spindle assembly checkpoint (SAC). Mutations that
reduce BubR1 abundance cause aneuploidization and tumorigenesis in humans and mice, whereas
BubR1 overexpression protects against these. However, how supranormal BubR1 expression exerts
these beneficial physiological impacts is poorly understood. Here, we used Bub1b mutant
transgenic mice to explore the role of the amino-terminal (BubR1N) and internal (BubR1I) Cdc20-
binding domains of BubR1 in preventing aneuploidy and safeguarding against cancer. BubR1N was
necessary, but not sufficient to protect against aneuploidy and cancer. In contrast, BubR1 lacking
the internal Cdc20-binding domain provided protection against both, which coincided with
improved microtubule-kinetochore attachment error correction and SAC activity. Maximal SAC
reinforcement occurred when both the Phe- and D-box of BubR1I were disrupted. Thus, while
under- or overexpression of most mitotic regulators impairs chromosome segregation fidelity,
certain manipulations of BubR1 can positively impact this process and therefore be therapeutically
exploited.
DOI: 10.7554/eLife.16620.001
Introduction
Chromosomal instability (CIN) describes a condition where cells frequently acquire cytogenetic alter-
ations and do not accurately segregate their chromosomes (Giam and Rancati, 2015). Aneuploidy,
defined as a state in which there are alterations to whole chromosome copy number, results from
CIN and is a feature of almost all tumors, but whether aneuploidy is a cause or consequence of trans-
formation is the subject of much debate (Ricke and van Deursen, 2013). CIN is thought to allow
pre-neoplastic cells to acquire genes that promote tumor progression and lose those which suppress
transformation (Baker et al., 2009; Burrell et al., 2013; Hanahan and Weinberg, 2011; Loeb, 2011)
and there are multiple lines of evidence which support aneuploidy having a causative role for cancer.
For instance, several human aneuploidy syndromes are characterized by increased susceptibility to
cancer, including trisomies 8, 18 (Edwards syndrome) and 21 (Down Syndrome) (Ganmore et al.,
2009), and mosaic variegated aneuploidy (MVA) (Hanks et al., 2004; Snape et al., 2011). Further-
more, bidirectional deviations in protein levels of various mitotic regulators, including Mad2, Mad1
and Bub1, cause aneuploidy and tumor predisposition in mice (Iwanaga et al., 2007;
Jeganathan et al., 2007; Michel et al., 2001; Ricke et al., 2011; Ryan et al., 2012; Sotillo et al.,
2007). Additionally, modulations to a spectrum of other proteins that participate in diverse cellular
functions, such as the E2 ubiquitin-conjugating enzyme Ubch10 (van Ree et al., 2010), the centro-
mere-linked microtubule protein CENP-E (Weaver et al., 2007), and the nuclear pore complex pro-
tein Nup88 (Naylor et al., 2016) result in aneuploidy and accelerated cancer progression. Finally,
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genome-wide screens of proteins that negatively (STOP) and positively (GO) regulate proliferation
are recurrently and selectively lost and gained respectively in either focal regions or whole chromo-
somes (Davoli et al., 2013; Solimini et al., 2012). This suggests a model where changes in gene
copy number are under selection rather than simply accompanying transformation, supporting geno-
mic instability as a driver of cancer (Davoli et al., 2013; Solimini et al., 2012). On the other hand,
several other mouse models of CIN have revealed inconsistent results regarding the relationship
between aneuploidy and cancer, where some mouse models with elevated levels of aneuploidy do
not show increased susceptibility to cancer (Babu et al., 2003; Kalitsis et al., 2005; Ricke et al.,
2012). Furthermore, proteotoxic stress from increased gene expression in cells with extra chromo-
some copies has adverse effects on cell growth and may thus counteract cancer progression
(Tang et al., 2011; Williams et al., 2008).
Aneuploidy results when cells fail to segregate chromosomes properly. To promote high-fidelity
separation of duplicated chromosomes, cells have the machinery to safeguard against missegrega-
tion. One such mechanism is the spindle assembly checkpoint (SAC). This surveillance system pre-
vents activation of the E3 ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C) by its
co-activator, Cdc20 (Peters, 2006). This ensures chromosomal stability by preventing sister chroma-
tid separation prior to bi-orientation of mitotic chromosomes at the metaphase plate
(Musacchio and Salmon, 2007). An additional measure to promote accurate chromosome segrega-
tion is allowing sufficient time to form proper and correct erroneous kinetochore-microtubule (MT-
KT) attachments prior to anaphase onset (Meraldi et al., 2004). Merotely, a type of improper attach-
ment in which a single kinetochore is attached to microtubules emanating from both spindle poles,
is undetected by the SAC and can result in lagging chromosomes (Cimini et al., 2001; Rodriguez-
Bravo et al., 2014). Mad1/2, Mps1, and BubR1 specify the minimum time in mitosis, and loss of
these proteins reduces the duration of mitosis and increases the rates of missegregation
(Maciejowski et al., 2010; Meraldi et al., 2004; Rodriguez-Bravo et al., 2014).
eLife digest Human DNA is organized into 46 chromosomes, which must be duplicated before
a cell divides and are then shared equally between the two new cells. When this process goes awry,
the new cells either have too many or too few chromosomes. This situation – known as aneuploidy –
frequently occurs in cancer cells, and is thought to cause cells to gain extra copies or lose copies of
genes that promote or prevent cancer, respectively.
Cells have several ways to prevent aneuploidy. One of these safeguards, known as the spindle
assembly checkpoint (SAC), involves a protein called BubR1, which acts at the stage when the
duplicated chromosomes need to be equally divided into each daughter cell. Mouse models show
that low levels of the BubR1 protein result in aneuploidy and increased predisposition to cancer.
High levels of BubR1, on the other hand, allow the mice to stay healthier for longer and can stop
tumors from forming. However, it was not known exactly how high amounts of BubR1 protect
against cancer.
To address this question, Weaver et al. set out to determine which parts, or domains, of the
BubR1 protein protect against cancer. Mice with high levels of the full-length BubR1 protein were
compared with mice that made mutant versions of BubR1 lacking certain domains. These
experiments revealed that a small portion of the beginning of the protein was necessary to protect
against tumor formation, but removing a large region in the middle of BubR1 still protected mice
against lung cancer and aneuploidy. Additional experiments performed on mouse cells grown in the
laboratory revealed that whole BubR1 protein and the mutant protein lacking the middle region
might prevent aneuploidy in multiple ways. For example, both systems had stronger SAC signaling,
which could serve to make segregating the chromosomes more accurate.
In the future, it will be important to find out whether BubR1 acts in the same way in human cells
and cancers. Lastly, since it is not possible to over-produce BubR1 in humans, other methods will
need to be investigated to use this knowledge to treat cancer.
DOI: 10.7554/eLife.16620.002
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BubR1, along with Mad2 and Bub3, is a component of the mitotic checkpoint complex (MCC),
which mediates the SAC (Kulukian et al., 2009; Musacchio and Salmon, 2007; Sudakin et al.,
2001). Once each chromosome has properly and stably attached to the mitotic spindle and sufficient
inter-kinetochore tension is generated, the MCC dissociates, allowing Cdc20 to activate the APC/C
(Musacchio and Salmon, 2007). Co-activation of APC/C by Cdc20 in metaphase results in the polyu-
biquitination and subsequent proteasomal degradation of cyclin B1 and securin, thereby triggering
sister chromatid separation and anaphase onset (Kapanidou et al., 2015; Musacchio and Salmon,
2007). BubR1, encoded by the gene Bub1b in mice or BUB1B in humans, is a modular protein, with
several known functional domains that together ensure mitotic fidelity and genome stability. BubR1
localizes to the kinetochore by interacting through its GLEBs-like motif with Bub3 (Elowe et al.,
2010; Lampson and Kapoor, 2005). In human cells, kinetochore-localized BubR1 was shown to be
important for MT-KT stabilization through an internally located kinetochore attachment and regula-
tory domain (KARD) (Suijkerbuijk et al., 2012). The KARD allows kinetochore localization of the
phosphatase PP2A, which counteracts the MT-KT destabilizing activity of Aurora B kinase, a key
mediator of error-correction (Ruchaud et al., 2007; Suijkerbuijk et al., 2012). Additional BubR1
functional domains include a putative kinase/pseudokinase domain that has been reported to rein-
force the SAC and stabilize MT-KT attachments (Elowe, 2011; Harris et al., 2005;
Suijkerbuijk et al., 2012) and two Cdc20-binding domains, of which the N-terminal domain
(BubR1N) is a critical APC/CCdc20 inhibitor essential for cell survival (Malureanu et al., 2009). BubR1N
contains two KEN-boxes, spanning amino acids 19–21 (KEN1) and 298–300 (KEN2) in mice, that in
conjunction with a destruction (D)-box (D1) just downstream of KEN2 permits BubR1 to behave as a
pseudo-substrate inhibitor of APC/CCdc20(Burton and Solomon, 2007; Chao et al., 2012;
Han et al., 2013; Izawa and Pines, 2015; Malureanu et al., 2009). Recent work has highlighted
that BubR1 is capable of binding both soluble Cdc20 through KEN1 to prevent APC/C-Cdc20 associ-
ation, and a second Cdc20 that has already bound to and activated the APC/C through a combina-
tion of KEN2 and D1 for even more dynamic APC/CCdc20 inhibition (Izawa and Pines, 2015).
The second Cdc20-binding domain of BubR1, BubR1I, is an internally located and functionally dis-
tinct region important for Cdc20 kinetochore recruitment, and has been proposed to serve a dual
function in SAC activation and silencing (Chao et al., 2012; Di Fiore et al., 2015; Diaz-
Martinez et al., 2015; Izawa and Pines, 2015; Lischetti et al., 2014; Tang et al., 2001). Several
conserved and somewhat redundant motifs within BubR1I were recently identified that are thought
to promote the BubR1-Cdc20 interaction through complementary mechanisms: the ABBA motif,
named for its conserved presence in Acm1, Bub1, BubR1 and Cyclin A (Di Fiore et al., 2015); the
Phe box, a phenylalanine-containing region which is encompassed within the ABBA motif (Diaz-
Martinez et al., 2015); and a D-box just downstream of the Phe Box (D-box2) (Diaz-Martinez et al.,
2015).
Whereas bidirectional changes to protein levels of Mad1, Bub1 and Mad2 cause aneuploidy and
tumorigenesis (Ricke and van Deursen, 2013), BubR1 is unique amongst mitotic regulators in that
both under- and overexpression results in drastically different phenotypes (Baker et al., 2013;
Baker et al., 2004). Complete loss of BubR1 causes early embryonic death (Wang et al., 2004), and
while BubR1 hypomorphic (Bub1bH/H) mice are viable, they develop a variety of premature aging
phenotypes (Baker et al., 2004; Hartman et al., 2007; Kyuragi et al., 2015; Matsumoto et al.,
2007; North et al., 2014), progressive aneuploidy (Baker et al., 2004), and are predisposed to car-
cinogen-induced cancers (Baker et al., 2006). Additionally, in humans, mutations in BUB1B have
been causally implicated in MVA, a rare clinical syndrome characterized by widespread aneuploidy,
growth retardation, shortened lifespan, and cancer predisposition (Garcı´a-Castillo et al., 2008;
Hanks et al., 2004; Matsuura et al., 2006; Wijshake et al., 2012). Conversely, overexpression of
BubR1 extends life- and healthspan of mice, decreases the tumor incidence, and provides protection
against age-related phenotypes in tissues that are prone to increased aneuploidy rates with age
(Baker et al., 2013).
Despite profound anti-tumor and anti-aneuploidization effects of BubR1 overexpression, the
molecular mechanism(s) of how it prevents CIN and cancer remains unclear (Baker et al., 2013).
Here, we focus on the role of BubR1-Cdc20 binding, and explore how this interaction reinforces the
SAC and error-correction machinery by using a series of transgenic mice overexpressing BubR1
mutants with disruptions in Cdc20-binding domains. We show that overexpression of a mutant
BubR1 that includes disruptions of the internal Cdc20-binding domain (BubR1DI) elicits a tumor-
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protective mechanism similar to that of full-length (FL)-BubR1 overexpression. Importantly, like in FL-
Bub1b, overexpression of this mutant also safeguards against aneuploidization, likely by both
strengthening SAC signaling and preventing improper KT-MT attachments. Thus, the internal
Cdc20-binding domain is dispensable to mediate these protective effects, while the N-terminal
Cdc20-binding domain is necessary, but not sufficient. BubR1DI also provides distinct molecular
properties unique to that of overexpression alone that also likely promote genetic stability and show
no overt detrimental effects on cells or mice. This includes a more robust SAC that is more respon-
sive to weak stimuli, and an increase in the normal length of mitosis. With further refined mutant
Bub1b constructs, we demonstrate that a maximal SAC response can be achieved exclusively by the
loss of the Phe box and D-box2, and that the mitotic timing may be dependent on previously
uncharacterized regions of BubR1. Importantly, this work sheds light on the causal role of CIN in can-
cer by demonstrating that enhancing genomic stability fortifies the barriers of transformation, and
may provide unique insights into the generation of new therapeutic strategies.
Results
Generation of transgenic mice overexpressing BubR1 mutants
To determine the role of the N-terminal and internal Cdc20-binding domains in the protective effect
of BubR1 overexpression on aneuploidy and cancer, we generated three distinct Flag-tagged mutant
Bub1b transgenic mouse strains (Figure 1A). The first two mutants lacked either residues 1–363 con-
taining the N-terminal Cdc20-binding domain (Bub1bDN) or residues 525–700 (Bub1bDI) which dis-
rupts the Phe box, and removes D-box2 and KARD. The third mutant contained only the N-terminal
Cdc20-binding domain (Bub1bN). Like FL-Bub1b, all three mutants were expressed under the control
of the ubiquitously active CAAGS promoter (Baker et al., 2013). Enhanced green fluorescent pro-
tein (EGFP) was co-expressed from an internal ribosome entry site (IRES). Western blots of mouse
embryonic fibroblasts (MEFs) and lung tissue from 5-month old mice revealed that each of the three
BubR1 mutants was expressed at levels comparable to that of FL-BubR1 (strain T23; Figure 1B, and
Figure 1—figure supplement 1).
BubR1 is unique among mitotic regulators in that its overexpression does not lead to chromo-
some missegregation and aneuploidization and actually protects cells against chromosomal instabil-
ity and karyotypic abnormalities (Baker et al., 2013; Ricke et al., 2011; Ryan et al., 2012;
Sotillo et al., 2007). To examine whether the Bub1b mutants we created negatively impacted karyo-
type integrity, we performed chromosome counts on metaphase spreads of MEFs derived from
wild-type and Bub1b transgenic MEFs (Table 1). There was no significant difference in aneuploidy
rates between FL-Bub1b, Bub1bN, Bub1bDI and wild-type MEFs, whereas Bub1bDN MEFs had
increased aneuploidy. However, these aneuploidy-prone MEFs did not have higher rates of chromo-
some segregation errors as assessed by live cell imaging (Table 2). As expected, missegregation
rates for the FL-Bub1b, Bub1bN, and Bub1bDI mutants were normal. By interphase FISH, none of the
transgenic mouse lines, including Bub1bDN, showed evidence of elevated aneuploidy rates in a
broad spectrum of mouse tissues and organs collected from 5-month-old mice (Table 3). Altogether,
these data indicated that our transgenic mutant lines could provide the framework necessary to
characterize the benefits of FL-BubR1 overexpression.
BubR1 N-terminus is necessary but not sufficient to protect against
cancer and aneuploidy
In earlier studies, we found that overexpression of FL-BubR1 markedly inhibits lung tumor formation
in KrasLA1 mice, a genetically engineered strain carrying a conditional oncogenic Kras allele
(KrasG12D) that becomes active upon intrachromosomal homologous recombination (Baker et al.,
2013; Johnson et al., 2001). Given the robustness of this tumor protection, we used KrasLA1 mice
to explore the role of the amino-terminal and internal Cdc20-binding domains in the tumor protec-
tive effect of BubR1 overexpression on cancer. Consistent with our previously published data
(Baker et al., 2013), overexpression of FL-BubR1 had a tumor-protective effect (Figure 2A–C).
Bub1bN and Bub1bDN, however, were unable to ameliorate the tumor burden of KrasLA1 mice, indi-
cating that binding of Cdc20 mediated by the N-terminal domain is necessary, but not sufficient, to
protect against tumor formation. In contrast, Bub1bDI fully retained the tumor-protective benefit of
Weaver et al. eLife 2016;5:e16620. DOI: 10.7554/eLife.16620 4 of 26
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DOI: 10.7554/eLife.16620.003
The following figure supplement is available for figure 1:
Figure supplement 1. Analysis of BubR1 overexpression in transgenic MEFs.
DOI: 10.7554/eLife.16620.004
Weaver et al. eLife 2016;5:e16620. DOI: 10.7554/eLife.16620 5 of 26
Research article Cancer Biology Genes and Chromosomes
FL-Bub1b. In addition to adenomas, KrasG12D produces a hyperplastic epithelium throughout the
lung, which is prone to aneuploidization as evidenced by FISH for chromosomes 4 and 7 (Figure 2B,
D) (Baker et al., 2013). Analysis of hyperplastic lung tissue from KrasLA1 mice containing the FL-
Bub1b transgene revealed that BubR1 overexpression has the ability to counteract KrasG12D-medi-
ated aneuploidization (Baker et al., 2013). Using FISH analysis, mice expressing the various Bub1b
mutant transgenes revealed that tumor protection tightly correlated with an ability to counteract
KrasG12D-mediated aneuploidization (Figure 2D). Taken together, these data are consistent with the
idea that BubR1 exerts its anti-neoplastic actions by preserving genomic integrity and suggest that
only a subset of functional domains of BubR1 are necessary to afford protection against aneuploid-
ization, which includes the N-terminal domain required for potent inhibition of APC/CCdc20
(Malureanu et al., 2009).
Protection against aneuploidy and cancer correlates with increased
BubR1 at kinetochores
To understand the molecular mechanism(s) underlying BubR1’s protective qualities, we conducted
an extensive comparative analysis between MEFs from transgenics expressing FL-BubR1 and our
BubR1 mutants for their ability to engage pathways that safeguard against chromosome missegrega-
tion, including the SAC and the MT-KT attachment error correction machinery. First, we focused on
BubR1-kinetochore localization, as this property has been shown to be important for its role in both
error correction and SAC signaling (Malureanu et al., 2009). By immunostaining with antibodies
Table 1. Karyotypes are stable in select BubR1 mutant overexpressing MEFs. Karyotype analysis of passage 5 MEFs of indicated
genotype. n  3 lines, 50 cells per line. Data are mean ± s.d. WT, wild-type. FL, full-length. (See associated Table 1— source data 1).
Mitotic MEF
genotype (n) Mitotic figures
Aneuploid
figures % (s.d)
Karyotype with indicated chromosome number
36 37 38 39 40 41 42 43 44
WT (5) 250 9 (6) 1 1 0 5 227 9 7 0 0
FL-Bub1b (3) 150 10 (3) 0 0 1 2 135 7 5 0 0
Bub1b
DI (3) 150 8 (3) 0 0 1 2 138 9 0 0 0
Bub1b
DN (5) 250 18 (6)* 0 0 2 15 204 23 6 0 0
Bub1b
N (3) 150 6 (2) 0 0 1 3 141 4 1 0 0
*p<0.05.
DOI: 10.7554/eLife.16620.005
Source data 1. Source file for MEF aneuploidy rate data.
DOI: 10.7554/eLife.16620.006
Table 2. Bub1b transgenic MEFs have normal missegregation rates. Live-cell imaging of chromosome segregation defects in primary
H2B-RFP MEFs of indicated genotypes. n  3 lines,  20 cells per line. Data are mean ± s.e.m. WT, wild-type. FL, full-length. (See
associated Table 2—source data 1).
MEF
genotype (n)
Mitotic cells
inspected
Cells with
segregation defects
Metaphases with misaligned
chromosomes
Anaphases with lagging
chromosomes
Anaphases with bridges
chromosome
% (s.e.m) % (s.e.m) % (s.e.m) % (s.e.m)
WT (3) 94 16 (1) 0 (0) 6 (3) 13 (1)
FL-Bub1b (3) 105 17 (2) 3 (3) 3 (2) 11 (2)
Bub1b
DI (3) 105 12 (1) 1 (1) 1 (1) 10 (1)
Bub1b
DN (3) 101 19 (1) 1 (1) 7 (1) 11 (2)
Bub1b
N (3) 95 17 (6) 3 (2) 2 (2) 12 (6)
DOI: 10.7554/eLife.16620.007
Source data 1. Source file for missegregation assay data.
DOI: 10.7554/eLife.16620.008
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directed against the BubR1 N-terminus, we found that both FL-Bub1b and Bub1bDI prometaphases
had markedly increased amounts of BubR1 compared to wild-type MEFs (Figure 3A,B). Due to anti-
body limitations, we were unable to distinguish the ratio of kinetochore-localized endogenous to
transgenic BubR1 within the mutant MEFs, with the exception of Bub1bN, in which only endogenous
protein can be detected. This illuminated that endogenous BubR1 was displaced from the kineto-
chore, but we cannot rule out that the other mutants also had lower endogenous levels at the kinet-
ochore, which is likely due to increased abundance of mutant protein within the cell. By staining with
a Flag antibody that recognizes only the transgenic BubR1 protein, we determined that the relative
expression of BubR1DI was slightly higher than FL-BubR1, while BubR1N was equivalent to FL-BubR1
Table 3. Bub1b transgenic mice have normal rates of aneuploidy in vivo. Interphase FISH on
specified tissues from mice of indicated genotypes. n = 3 animals, 100 cells per tissue per animal.
Data are mean ± s.d. WT, wild-type. FL, full-length. (See associated Table 3—source data 1).
Percentage of aneuploidy (s.d)
Tissue Type Genotype Chrom 4 Chrom 7
Lung WT 1.3 (0.6) 3.0 (0)
FL-Bub1b 2.3 (0.6) 2.0 (1)
Bub1b
DI 2.0 (0) 2.3 (0.6)
Bub1b
DN 3.0 (1) 2.3 (0.6)
Bub1b
N 2.3 (0.6) 2.3 (0.6)
Heart WT 2.0 (1) 1.7 (0.6)
FL-Bub1b 1.3 (0.6) 2.0 (1)
Bub1b
DI 1.3 (0.6) 2.0 (0)
Bub1b
DN 1.7 (1.2) 2.0 (1)
Bub1b
N 1.3 (0.6) 1.7 (0.6)
Eye WT 2.0 (0) 2.0 (1)
FL-Bub1b 2.0 (0) 2.3 (0.6)
Bub1b
DI 1.7 (0.6) 1.3 (0.6)
Bub1b
DN 2.0 (1) 2.3 (0.6)
Bub1b
N 1.7 (0.6) 2.0 (0)
Kidney WT 2.0 (1) 2.0 (1)
FL-Bub1b 2.3 (0.6) 2.0 (0)
Bub1b
DI 2.0 (1) 1.3 (0.6)
Bub1b
DN 2.7 (0.6) 2.0 (0)
Bub1b
N 2.0 (1) 1.3 (0.6)
Spleen WT 3.3 (0.6) 2.3 (1.2)
FL-Bub1b 3.0 (1) 2.0 (1)
Bub1b
DI 2.0 (1) 1.7 (0.6)
Bub1b
DN 3.0 (1) 2.7 (0.6)
Bub1b
N 2.7 (0.6) 3.0 (0)
Skeletal muscle WT 2.3 (0.6) 2.6 (0.6)
FL-Bub1b 2.7 (0.6) 2.0 (0)
Bub1b
DI 2.0 (0) 2.0 (1)
Bub1b
DN 2.3 (1.2) 2.7 (0.6)
Bub1b
N 2.0 (0) 2.3 (0.6)
DOI: 10.7554/eLife.16620.009
Source data 1. Source file for tissue aneuploidy rate data.
DOI: 10.7554/eLife.16620.010
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(Figure 3C,D). BubR1DN, which did not protect against cancer, failed to localize to kinetochores,
consistent with a lack of the GLEBs motif (Lampson and Kapoor, 2005). Taken together, these data
demonstrate a likely need for BubR1 to retain functionality, perhaps mediated through the N-termi-
nal domain, at the kinetochore to prevent aneuploidy and tumorigenesis.
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Figure 2. Select BubR1 domain overexpression protects against aneuploidy and cancer. (A) Lung lobes of KrasLA1 mice and KrasLA1 mice expressing
various BubR1 transgenic proteins sacrificed at 6 weeks of age. Entire lungs were inspected using a dissection microscope to quantitate the number of
lung tumors (adenomas) per mouse. (B) Hematoxylin-eosin stained lung sections of representative normal (WT) lung and a KrasLA1 (Kras) hyperplastic
tumor-bearing lung (the dashed line marks the adenoma boundary). Insets highlight normal and hyperplastic lung architecture. (C) Quantification of
the number of lung tumors from mice shown in A. n = 20, except for full-length (FL)-Bub1b where n = 7. Data are mean ± s.e.m. ***p<0.001. (D)
Interphase FISH on the lungs of wild-type and KrasLA1 with and without FL-BubR1 and mutant overexpression. n = 5,  100 cells per animal. Data are
mean ± s.d. *p<0.05, **p<0.01. ***p<0.001. Scale bars: A, 2 mm; B, 200 mm (main image) and 50 mm (insets). (See associated Figure 2—source data 1).
DOI: 10.7554/eLife.16620.011
The following source data is available for figure 2:
Source data 1. Source file for tumor incidence and tissue aneuploidy rate data.
DOI: 10.7554/eLife.16620.012
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Figure 3. Increased BubR1 localization to kinetochore corresponds to phenotypic benefits. (A) MEFs of indicated genotypes were stained for BubR1
(red), centromeres (cyan), and DNA (blue). WT, wild-type. FL, full-length. (B) Quantification of immunostaining of BubR1 shown in A. Values were
normalized to centromere stain and are relative to wild-type. n = 3 lines,  10 cells per line. Data are mean ± s.d. *p<0.05, ***p<0.001. (C) Same as in A
except with anti-Flag antibody to detect transgenic BubR1. (D) Quantification of immunostaining of Flag shown in C. Values were normalized to
centromere stain and are relative to wild-type. Wild-type and Bub1bN represent background. n = 3 lines,  10 cells per line. Data are mean ± s.d.
*p<0.05, **p<0.01, ***p<0.001. Scale bar 10 mm. (See associated Figure 3—source data 1).
DOI: 10.7554/eLife.16620.013
The following source data is available for figure 3:
Source data 1. Source file for intensity of kinetochore-localized BubR1 and FLAG protein data.
DOI: 10.7554/eLife.16620.014
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BubR1DI extends metaphase and improves SAC sustainability
BubR1, Mad2, and Mps1 kinase set the speed limit for mitosis (Meraldi et al., 2004), and perturba-
tions of these proteins accelerate mitotic timing and promote erroneous chromosome segregation
(Rodriguez-Bravo et al., 2014). Therefore, we sought to determine the effect of FL-BubR1 and
mutant BubR1 overexpression on mitotic timing by following MEFs from nuclear envelope break-
down (NEBD) to anaphase onset by time-lapse microscopy (Figure 4A). Because errors such as mis-
alignments that may be caused by unattached kinetochores can trigger the SAC to delay mitotic
progression, only cells that proceeded through mitosis without missegregation defects were
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Figure 4. Bub1bDI MEFs have an increased time in mitosis and duration of mitotic arrest. (A) Representative time-lapse images of live MEF cells of
indicated genotypes progressing from prophase (t = 0) to anaphase (A). Time is indicated in min. WT, wild-type. P, prophase. M, metaphase. (B)
Analysis of the time from nuclear envelope breakdown (NEBD) to anaphase onset in H2B-RFP MEFs of the indicated genotypes by live cell time-lapse
imaging. n = 3 lines,  20 cells per line. Data are mean ± s.d. **p<0.01. FL, full-length. (C) In a nocodazole challenge, H2B-RFP MEFs of indicated
genotypes were treated with 100 ng/ml of nocodazole (noc) and monitored by live cell time-lapse imaging. The point of time in which 50% of cells are
arrested in mitosis is plotted. n  3 lines,  20 cells per line. Data are mean ± s.d. *p<0.05, **p<0.01. (D) H2B-RFP wild-type and mutant transgenic
MEFs were treated concurrently with 100 ng/ml nocodazole and indicated concentrations of the Mps1 kinase inhibitor, AZ3146. The point of time in
which 50% of cells are arrested in mitosis is plotted. n = 3 lines,  20 cells per line. Data are mean ± s.d. *p<0.05. Scale bar, 10 mm (See associated
Figure 4—source data 1).
DOI: 10.7554/eLife.16620.015
The following source data and figure supplement are available for figure 4:
Source data 1. Source file for mitotic timing and nocodazole arrest data.
DOI: 10.7554/eLife.16620.016
Figure supplement 1. Bub1bDI MEFs do not have persistent Mad2 signaling.
DOI: 10.7554/eLife.16620.017
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included. Overexpression of FL-BubR1 had no impact on mitotic timing and the same was true for
BubR1N and BubR1DN (Figure 4B). In contrast, Bub1bDI MEFs spent significantly more time in mitosis
(Figure 4A,B). The increase in mitotic timing was specifically attributed to the metaphase-to-ana-
phase transition, where Bub1bDI MEFs spent more than twice as long.
To verify that the extended time in mitosis was not due to unattached chromosomes, we per-
formed an immunostaining for Mad2, which strongly localizes to unattached kinetochores
(Waters et al., 1998). We found that while prometaphases of wild-type, FL-Bub1b and Bub1bDI
MEFs had many Mad2-positive kinetochores, there were very rare incidences of Mad2-positive kinet-
ochores in metaphase (Figure 4—figure supplement 1). This indicated that the increased time of
the metaphase-to-anaphase transition was delayed independent of unattached chromosomes or oth-
erwise persistent Mad2 signaling. The extension of mitotic timing is a feature that is not shared with
FL-overexpression alone, indicating it likely has a minimal contribution to tumor protection in our
Kras model. However, it is particularly intriguing as a mechanism to prevent aneuploidy, as KT-MT
attachment errors that are not detected by the SAC, namely merotelic attachments, may perhaps be
given extra time to allow for the error correction machinery to prevent missegregation (Cimini et al.,
2001; Rodriguez-Bravo et al., 2014).
Next, we examined whether overexpression of BubR1 and its variants impacted SAC sustainabil-
ity. To do this, we added 100 ng/ml of the microtubule depolymerizing agent nocodazole and moni-
tored the amount of time individual cells stayed arrested in mitosis. FL-BubR1 overexpression
caused a slight but significant increase in duration of arrest, with transgenic cells arresting on aver-
age for 3.7 hr compared to 3 hr for wild-type MEFs (Figure 4C). Bub1bN MEFs were unchanged
from wild-type, while Bub1bDN MEFs actually had a slight but significant reduction in arrest time. In
contrast, Bub1bDI MEFs showed a dramatic extension of checkpoint sustainability, with cells arresting
for an average time of 6.2 hr. Thus, the two BubR1 alterations offering tumor protection, overex-
pression of FL-BubR1 and BubR1DI, improve checkpoint sustainability although the latter does so
much more robustly. In complementary experiments, we challenged the SAC by inhibiting Mps1, a
kinase necessary both for the establishment and maintenance of the SAC (Hewitt et al., 2010;
Liu and Winey, 2012). Treatment of MEFs concomitantly with 100 ng/ml nocodazole and a high
concentration of the Mps1 inhibitor AZ3146 (2 mM) completely abolished SAC activity irrespective of
the Bub1b transgene expressed (Figure 4D). At a four-fold lower inhibitor concentration, wild-type,
Bub1bN, Bub1bDN MEFs were all capable of mounting a modest mitotic arrest. The relative exten-
sion of mitotic arrest in FL-Bub1b and Bub1bDI MEFs, however, was considerably higher, with
Bub1bDI MEFs reaching a similar level of SAC signaling in the presence of 0.5 mM AZ3146 as wild-
type MEFs in the absence of inhibitor (Figure 4D). Thus, under normal SAC conditions and condi-
tions where the SAC signaling is weakened, both BubR1DI and FL-BubR1overexpression seem capa-
ble of prolonging mitotic arrest, albeit to different degrees.
BubR1DI lowers the threshold for SAC activation
Because the internal Cdc20-binding domain of BubR1 has been implicated in both initiating and
silencing the mitotic checkpoint (Diaz-Martinez et al., 2015; Lischetti et al., 2014), we hypothe-
sized that FL-Bub1b and Bub1bDI MEFs may have a lower threshold of checkpoint activation or a dif-
ficulty silencing the checkpoint, or both. To examine whether FL-Bub1band Bub1bDI MEFs might
have a lower threshold for SAC activation, we challenged them with low concentrations of nocoda-
zole and monitored time to anaphase onset (Figure 5A). Based on the response of wild-type MEFs,
we found that 20 ng/ml was the optimal dose to use in this experiment (Figure 5A). At this dose,
however, the time Bub1bDI MEFs took to go through mitosis increased by 60% compared to
increases of ~25% in wild-type and FL-Bub1b MEFs, suggesting that these MEFs had a lower thresh-
old for SAC activation.
Next, we sought to determine whether these MEFs also had difficulty in silencing the SAC. To
test this we used a live-cell imaging-based approach in which we cultured MEFs in 100 ng/ml noco-
dazole for 1.5 hr to activate the SAC and then monitored mitotically-arrested cells for time to mitotic
exit following treatment with either vehicle (DMSO) or 2 mm AZ3146 as a stimulus for dissolving
MCCs (Figure 5B). In this assay, neither FL-BubR1 nor BubR1DI overexpression permitted an arrest
longer than that observed in wild-type MEFs. Additionally, while BubR1-associated PP2A has been
shown to be important for error correction in human cells (Suijkerbuijk et al., 2012), it is also impor-
tant for silencing the SAC (Espert et al., 2014). As BubR1DI lacks the KARD region implicated in
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PP2A recruitment, its overexpression could potentially mislocalize PP2A and impede proper SAC
silencing. We found PP2A localization to be normal in BubR1DI overexpressing cells, suggesting this
branch of signaling is not impacted (Figure 5—figure supplement 1), and further supporting that
silencing of the SAC is not disrupted. Taken together, these results suggest that the threshold to
engage the SAC is instead lowered by the Bub1bDI transgene.
The mitotic checkpoint complex composition is unique in Bub1bDI MEFs
To explore the mechanism as to why Bub1bDI and FL-Bub1b MEFs both had more robust checkpoint
signaling when challenged with nocodazole, we determined whether the amount of Cdc20 bound to
BubR1 was increased in these cells. To this end, we treated wild-type, Bub1bDI and FL-Bub1b MEFs
cells with nocodazole for 1 hr before harvesting them by mitotic shake-off. We found that overex-
pression of FL-BubR1 lead to increased interaction of BubR1 and Cdc20, as had been previously
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Figure 5. Bub1bDI MEFs have a lower threshold to checkpoint activation. (A) Analysis of the time from NEBD to anaphase onset in H2B-RFP MEFs of
the indicated genotypes treated with either DMSO vehicle (Veh) or indicated concentration of nocodoazole (Noc). n = 3 lines,  20 cells per line. Data
are mean ± s.d. *p<0.05, **p<0.01. WT, wild-type. FL, full-length. (B) (top) Strategy for analyzing the checkpoint silencing efficiency. MEFs of indicated
genotypes were treated with 100 ng/ml nocodazole for 1.5 hr before addition of either DMSO vehicle (Veh) or 2 mM AZ3146, at which point cells were
marked and monitored for time of escape (time point zero). (bottom) Analysis of duration of mitotic arrest from time point zero as outlined in (top). n =
3 lines,  20 cells per line. (See associated Figure 5—source data 1).
DOI: 10.7554/eLife.16620.018
The following source data and figure supplements are available for figure 5:
Source data 1. Source file for low-dose nocodazole challenge and SAC silencing data.
DOI: 10.7554/eLife.16620.019
Figure supplement 1. PP2A localization is normal in Bub1bDI MEFs.
DOI: 10.7554/eLife.16620.020
Figure supplement 1—source data 1. Source file for intensity of kinetochore-localized PP2A protein data.
DOI: 10.7554/eLife.16620.021
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shown (Figure 6A) (Baker et al., 2013). This was confirmed by Cdc20 and Mad2 co-IPs and subse-
quent analysis of co-precipitating proteins (Figure 6B,C) that indicated there were an increased
amount of complexes consisting of BubR1-Cdc20-Mad2, a potent APC/C inhibitor. However, we
found that while the total amount of BubR1 (wild-type and mutant) immunoprecipitated in Bub1bDI
MEFs is increased substantially over normal MEFs, BubR1 lacking the internal Cdc20-binding domain
failed to pull-down excess Cdc20 and vice versa (Figure 6A,C). This suggests that while BubR1DI can
likely bind to Cdc20, it is not a preferred partner. Surprisingly, the amount of Mad2 co-precipitated
by Cdc20 was increased, indicating that a larger proportion of Cdc20 bound Mad2 than in wild-type
MEFs, while retaining similar levels of BubR1-Cdc20-Mad2 complexes as wild-type. Immunoprecipi-
tation of Mad2 and Cdc20 and analysis of co-precipitating MCC components confirmed this
(Figure 6B,C). These unique MCC compositions did not result from changes to total levels of these
proteins (Figure 6—figure supplement 1). Thus, FL-BubR1 overexpression alone results in the ability
for cells to form more mitotic checkpoint complexes compared to wild-type MEFs, which can likely
fortify the SAC signaling potential. Bub1bDI, however, exerts its impacts on the MCC through a dif-
ferent mechanism. The increased abundance of Mad2-Cdc20 complexes, albeit a weaker inhibitor of
APC/C than a full complement of the MCC, in addition to wild-type levels of MCC could represent a
state in which the cells are poised to quickly activate the SAC. This is supported by our data in which
Bub1bDI show increased sensitivity to a weak SAC-inducing stimulus (Figure 5A).
In complimentary experiments, we sought to determine if an MCC-independent mechanism could
also contribute to the extended SAC arrest of FL-Bub1b and Bub1bDI MEFs. In addition to being
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Figure 6. Composition of mitotic checkpoint complexes is unique in Bub1bDI MEFs. (A–D) Immunoblots of mitotic wild-type (WT) and indicated mutant
MEF extracts subjected to co-immunoprecipitation with the indicated antibodies. Each blot is a representative of at least 3 experiments. FL, full-length.
DOI: 10.7554/eLife.16620.022
The following figure supplement is available for figure 6:
Figure supplement 1. Mitotic checkpoint components have a normal expression in Bub1b transgenic MEFs.
DOI: 10.7554/eLife.16620.023
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incorporated into the MCC, Cdc20 is subject to two regulatory phosphorylation events that disrupt
its ability to activate the APC/C (Jia et al., 2016). We examined the phosphorylation status of two
residues of Cdc20 implicated in mediating this inhibition, S153 and S92 by Bub1 kinase and Plk1
kinase respectively, in wild-type, FL-Bub1b and Bub1bDI MEFs by Western blot (Figure 6D)
(Jia et al., 2016). We found the levels of phosphorylation of both these residues to be equivalent to
wild-type MEFs, suggesting this method of APC/C control is not hyperactive in our mutants.
Protection from aneuploidy and tumorigenesis correlates with
reinforced error correction
Next we investigated whether and how overexpressed FL-BubR1 and BubR1DI contributed to high-
fidelity chromosome segregation under mitotic duress by reinforcing the attachment error correction
machinery. To do so, we used the motor protein Eg5 inhibitor monastrol to induce syntelic attach-
ments, a malattachment type that presents as misaligned chromosomes and is resolved by the
attachment error correction machinery (Lampson et al., 2004). Because error correction is highly
efficient in wild-type MEFs, we challenged the machinery in our experimental system by limiting
Aurora B kinase activity with 10 nM of the small molecule inhibitor AZD1152 (Ricke et al., 2012). FL-
BubR1 and BubR1DI both significantly blunted the increase in syntelic attachments caused by hypo-
active Aurora B (Figure 7). In contrast, no such corrective effects were observed in the Bub1bDN or
Bub1bN mutants.
Refined BubR1DI mutants are capable of reinforcing error correction
and SAC signaling
At the time of transgenic design, BubR1 residues 525–700 were defined as the internal Cdc20
domain (Malureanu et al., 2009). However, subsequent studies have revealed that this region
includes at least three discrete functional units: the Phe-box, D-box2 and KARD, the first two of
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Figure 7. Overexpression of FL-BubR1 and BubR1DIimproves error correction rates. (A) Representative images of MEFs with aligned or misaligned
chromosomes after monastrol washout. White arrowhead depicts misaligned chromosome. (B) Analysis of chromosome misalignment in MEFs
expressing the indicated Bub1b transgenes. MEFs were treated with 100 mM monastrol for 1 hr and then with monastrol and 10 mM MG132 for 1 hr and
released for 90 min into MG132. Cells were treated with DMSO (Vehicle) or 10 nM AZD1152-HQPA (AZD) throughout the duration of the experiment. n
= 6 lines (25 cells per line were analyzed). Data are mean ± s.d. *p<0.05, **p<0.01. Scale bar, 10 mm. WT, wild-type. (See associated Figure 7—source
data 1).
DOI: 10.7554/eLife.16620.024
The following source data is available for figure 7:
Source data 1. Source file for monastrol washout data.
DOI: 10.7554/eLife.16620.025
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which function as non-redundant Cdc20-binding motifs (Diaz-Martinez et al., 2015; Lischetti et al.,
2014; Suijkerbuijk et al., 2012). This prompted us to study the extent to which BubR1 overexpres-
sion is able to preserve genomic stability when these functional units are deleted individually or in
combination (Figure 8). These mutants were expressed in wild-type primary MEFs using a lentiviral
expression system that allows for doxycycline inducible transgene expression. FL-BubR1 and BubR1DI
expressed in the same system were used as controls. We confirmed that each mutant was specifically
and highly overexpressed in the presence of doxycycline (Figure 8—figure supplement 1).
Next, we examined the impact on mitotic timing by live cell imaging (Figure 9A). Overexpression
of BubR1DI provided a similar extension to the metaphase-to-anaphase transition as MEFs derived
from Bub1bDI transgenic mice. However, none of the other deletion constructs changed the duration
of mitosis when overexpressed. An additional deletion mutant lacking the Phe box, D-box2 and the
KARD (Bub1bDPheDDKARD) was generated to test if combined deletion of all three motifs would mimic
Bub1bDI (Figure 9—figure supplement 1). Again, no extended mitotic timing was observed, imply-
ing that an unmapped domain within residues 525–700 regulates mitotic timing.
As expected, BubR1DI-expressing MEFs showed the most profound increase in the duration of
nocodazole-mediated arrest, while FL-BubR1 overexpression caused a moderate, but significant
increase (Figure 4B). Of our newly generated mutants, Bub1bDPhe, Bub1bDD and Bub1bDKARD
behaved like overexpression of FL-BubR1, while Bub1bDPheD phenocopied Bub1bDI. These findings
indicate that none of the individual domains is required for SAC reinforcement by high levels
of BubR1 and the combinatorial loss of both the Phe and D-box2 motifs is a requirement for robust
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Figure 8. Schematics of pTripZ-Flag-Bub1b mutants. Schematics of the pTripZ-Flag-Bub1b constructs. D, destruction-(D-)box. GLEBs, GLEBs-binding
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DOI: 10.7554/eLife.16620.026
The following figure supplement is available for figure 8:
Figure supplement 1. Protein levels of Bub1b deletion constructs in wild-type MEFs.
DOI: 10.7554/eLife.16620.027
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Figure 9. BubR1 deletion constructs extend nocodazole arrest and positively impact error attachment machinery. (A) Analysis of the time from nuclear
envelope breakdown (NEBD) to anaphase onset in H2B-RFP wild-type MEFs infected with the indicated constructs with and without the addition of
doxycycline (Dox) by live cell time-lapse imaging. n = 1 line,  20 cells per treatment. Data are mean ± s.e.m. ***p<0.001. FL, full-length. (B) In a
nocodazole challenge, H2B-RFP wild-type MEFs infected with the indicated constructs with and without the addition of Dox were treated with 100 ng/
ml of nocodazole and monitored by live cell time-lapse imaging. The point of time in which 50% of cells are arrested in mitosis is plotted. n = 1 line, 
15 cells per treatment. *p<0.05, **p<0.01, ***p<0.001. (C) Analysis of chromosome misalignment in wild-type MEFs infected with the indicated
constructs with and without addition of Dox. MEFs were treated with 100 mM monastrol for 1 hr and then with monastrol and 10 mM MG132 for 1 hr and
released for 90 min into MG132. Cells were treated with DMSO (Vehicle) or 50 nM AZD1152-HQPA (AZD1152) throughout the duration of the
experiment. n = 3 lines, 50 cells per line per treatment. Data are mean ± s.d. *p<0.05. (See associated Figure 9—source data 1).
DOI: 10.7554/eLife.16620.028
The following source data and figure supplements are available for figure 9:
Source data 1. Source file for mitotic timing, nocodazole challenge and monastrol washout data.
DOI: 10.7554/eLife.16620.029
Figure supplement 1. Combined loss of Phe, D-box2 and KARD does not impact mitotic timing.
DOI: 10.7554/eLife.16620.030
Figure supplement 1—source data 1. Source file for mitotic timing data.
DOI: 10.7554/eLife.16620.031
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checkpoint sustainability. When examined for the ability to improve microtubule-kinetochore attach-
ment error correction in monastrol washout assays with and without Aurora B inhibition, all mutants
did so to a similar extent as FL-BubR1 (Figure 9C), indicating that this feature of BubR1 overexpres-
sion is not impacted by any functional units in the central portion of BubR1. Altogether, our studies
using refined BubR1DI mutants indicate that individual domains within the 525–700 region are not
required for SAC and error correction reinforcement by BubR1 overexpression, and that maximal
SAC reinforcement is achieved when both internal Cdc20-binding motifs are absent.
Cells expressing oncogenic Kras are prone to microtubule-kinetochore
malattachment
Overexpression of FL-BubR1 and BubR1DI reduces tumor burden and aneuploidization in KrasLa1
mutant mice. To better understand the underlying mechanisms, we determined the type of mitotic
errors caused by oncogenic Ras in wild-type MEFs. We found that ectopic expression of KrasG12V
had no impact on timing of mitosis and SAC signaling (Figure 10A–C). On the other hand, in monas-
trol washout assays, KrasG12V-expressing MEFs produced significantly higher rates of misaligned
chromosomes over empty vector alone (Figure 10D). In complementary experiments in which we
monitored chromosome segregation errors by live cell imaging, KrasG12V-expressing MEFs showed a
remarkable increase in misaligned chromosomes (Figure 10E). Collectively, these data suggest that
oncogenic Kras cells may be particularly prone to syntelic attachments.
Discussion
BubR1 is different from other mitotic regulators in that supranormal expression improves numerical
chromosomal integrity. Although it will be impractical to overexpress BubR1 for therapeutic pur-
poses, increased insight into the molecular mechanisms underlying the positive effects of BubR1
overexpression might create entry points for development of novel anti-cancer treatments based on
small molecules that complement current therapies. As a first step, we focused on the roles of
BubR1’s Cdc20-binding domains. Here we show that overexpression of the BubR1 N-terminal region
is necessary, but not sufficient to prevent Kras-mediated aneuploidy and tumorigenesis, implying
that reinforcing pseudo-substrate inhibition of Cdc20-bound APC/C by BubR1 is a requirement but
entirely ineffective in isolation. In contrast to the N-terminal Cdc20-binding domain, a region span-
ning residues 525–700 that includes the elements of the internal Cdc20-binding domain and KARD,
is dispensable for the aneuploidy and tumor suppressing effects. Overexpression of BubR1 lacking
this region reinforced genomic stability and cancer protection in mice, despite dramatically altering
metaphase duration of regularly dividing, unchallenged, MEF cells. We find that key shared charac-
teristics of overexpressed FL-BubR1 and BubR1DI include increased kinetochore localization,
increased error correction ability and a more robust SAC, though at differing magnitudes. BubR1DI
overexpression was most extreme in altering the SAC in that it appeared to lower the threshold for
checkpoint activation and maintenance. By analyzing the mitotic phenotypes of more refined dele-
tion mutants, we determined that the profound length of nocodazole-induced mitotic arrest in this
mutant was likely provided by a combined loss of the Phe box and D-box2, which is in alignment to
a previous report showing that this region normally serves to shorten mitotic arrest times (Diaz-
Martinez et al., 2015). However, whether the increased duration of mitotic arrest is actively partici-
pating in attenuation of Kras-mediated tumorigenesis in either FL-Bub1b or Bub1bDI KrasLa1 mice is
unclear, as oncogenic Kras alone did not negatively impact SAC signaling in MEFs.
Another unique attribute of BubR1DI overexpression was its impact on normal mitotic timing. In
pursuing this phenotype, we found that while overexpression of BubR1DPheD recapitulated the robust
nocodazole arrest seen in Bub1b MEFs, it did not reproduce the extension of the metaphase-to-ana-
phase transition. We further explored this with a mutant BubR1 lacking a combination of the Phe
box, D-box2 and KARD (Bub1bDPheDKARD), but also did not see changes to mitotic timing. This sug-
gests that the loss of a region within BubR1 between residues 525 and 700, either alone or in combi-
nation with the aforementioned domains, might be responsible for influencing the duration of
mitosis. Further expansion of this notion could assign new functions related to timing to previously
unmapped regions of BubR1.
Our studies in MEFs which had been infected with oncogenic Kras illuminated that while they had
normal mitotic timing and SAC signaling, they had challenges with proper error correction
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machinery. Taken altogether, these data suggest that specific manipulations of BubR1 and subse-
quent protection against aneuploidy can occur through distinct complimentary mechanisms that
result in tumor protection. In FL-Bub1b and Bub1bDI, parameters that positively influence genomic
stability such as a robust SAC and improved error correction correlate with loss of Kras-mediated
aneuploidy and tumorigenesis. Therefore, it is tempting to speculate that the strongest mechanism
preventing aneuploidization in our Kras system might be a strengthening of the error correction
machinery. Given the heterogeneous nature of lung tumors compared to MEFs, however, it is possi-
ble that distinct challenges and defects can arise in Kras lung tumors that are not overtly evident in
MEFs.
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Figure 10. Oncogenic Kras increases microtubule-kinetochore malattachment. (A) Western blot of wild-type (WT) MEFs infected with pBABE-Puro-KRas
(G12V) or empty vector (EV). Blot was probed with the indicated antibody. Ponceau S was used to normalize loading. (B) Analysis of the time from
nuclear envelope breakdown (NEBD) to anaphase (A) onset in H2B-RFP wild-type MEFs infected with KrasG12V or EV by live cell time-lapse imaging. n =
1 line,  19 cells. Data are mean ± s.d. *p<0.05. M, metaphase (C) In a nocodazole challenge, H2B-RFP wild-type MEFs infected with KrasG12V or EV
were treated with 100 ng/ml of nocodazole and monitored by live cell time-lapse imaging. The point of time in which 50% of cells are arrested in
mitosis is plotted. n = 1 line,  20 cells. *p<0.05. (D) Analysis of chromosome misalignments in wild-type MEFs infected with KrasG12V or EV. MEFs were
treated with 100 mM monastrol for 1 hr and then with monastrol and 10 mM MG132 for 1 hr and released for 90 min into MG132. n = 1 line, » 200 cells.
*p<0.05. (E) Live-cell imaging of chromosome segregation defects in primary H2B-RFP wild-type MEFs infected with Kras or EV. n = 1 line, » 40 cells.
*p<0.05. (See associated Figure 10—source data 1).
DOI: 10.7554/eLife.16620.032
The following source data is available for figure 10:
Source data 1. Source file for mitotic timing, nocodazole challenge, missegregation assay and monastrol washout data.
DOI: 10.7554/eLife.16620.033
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Lung tissues with activated oncogenic Kras proceed through several morphological stages, includ-
ing regions of mild hyperplasia/dysplasia that have increased aneuploidy relative to normal lung tis-
sue, to small alveolar adenomas and finally culminating into overt carcinoma (Baker et al., 2013;
Johnson et al., 2001). We proposed two distinct but non-mutually exclusive mechanisms of tumor
protection. In the first mechanism, the impact of a hypersensitive SAC combined with an ability to
promote proper attachments and prevent misalignments by FL-BubR1 and BubR1DI simply prevents
genetic heterogeneity that facilitates cancer progression. Thus, while hyperplasia is still a feature of
the lungs, there is a block to full neoplastic transformation because necessary losses of tumor sup-
pressors and gains of cancer promoting genes are prevented.
The second scenario is that survival of pre-neoplastic cells within the hyperplastic tissue is
impacted by BubR1 overexpression, such that unstable cells have an increased propensity to die.
The competing-networks model proposes that two independent yet competing cell fates oppose
each other during mitotic arrest: death by caspase-mediated apoptosis or mitotic slippage resulting
from persistent cyclin B1 degradation due to incomplete SAC inhibition (Brito and Rieder, 2006;
Gascoigne and Taylor, 2008; Topham et al., 2015). Cells with prolonged mitotic arrest have a
greater chance and more time to accumulate death signals (Gascoigne and Taylor, 2008). Both
mutants have an impact on one arm of the competing network branches, as evidenced by their
increase in arrest time in mitosis, though BubR1DI appears to have a more significant contribution.
This could shift a given cell population towards death rather than survival. However, this hypothesis
remains to be rigorously tested in our model especially since oncogenic Kras-infected MEF cells do
not show evidence of a weakened mitotic checkpoint. We argue that taking advantage of an
extended arrest independent of whether or not the machinery functions normally could still be used
to promote cancer cell death, and that BubR1 overexpression would be an entry point to such thera-
pies. Along these lines, microtubules have been targeted in anti-cancer chemotherapy with much
success (Dumontet and Jordan, 2010). Furthermore, the use of Wee/Chk1 inhibitors which cause
cells to bypass the G2 checkpoint, force reliance on the SAC (Mc Gee, 2015). This could be
exploited and we would predict an increased susceptibility to microtubule poisons and cytotoxicity,
in particular with a system mimicking BubR1DI or BubR1DPheD overexpression.
Previously we reported a non-significant increase in the mitotic arrest time of MEFs overexpress-
ing FL-BubR1 when challenged with nocodazole relative to wild-type (Baker et al., 2013). Here, we
conclude, based on more in depth and sophisticated studies to test this aspect of SAC signaling,
that there is a modest but significant increase in SAC potency in these cells (Baker et al., 2013). Fur-
thermore, overexpression of BubR1DPhe, BubR1DD, and BubR1DKARD deletion constructs in wild-type
MEFs also provided a slight but significant increase in mitotic arrest time compared to controls, indi-
cating that they were analogous to FL-BubR1 overexpression alone. It is important to note that the
data provided by the extensive analysis of Bub1bDI and Bub1bDKARD MEFs are in disagreement with
previous work in human cells, where the KARD was proposed to provide the MT-KT attachment
function of BubR1 (Suijkerbuijk et al., 2012). In these studies, introducing exogenous BubR1 with a
mutated KARD into systems depleted of endogenous BubR1 have decreased PP2A kinetochore
localization, and subsequent chromosome alignment defects (Suijkerbuijk et al., 2012). In Bub1bDI
MEFs, however, we do not see increased alignment errors or decreased PP2A kinetochore localiza-
tion (Table 2, Figure 5—figure supplement 1) and both overexpressed BubR1DI and BubR1DKARD
actually have increased error correction capabilities (Figure 7B, Figure 9C). We emphasize that
unlike the studies by Suijkerbuijk and colleagues, our transgene and deletion construct are on the
background of a full complement of endogenous BubR1, which may still provide adequate kineto-
chore docking of PP2A. Furthermore, our data are also in alignment with our previous work in which
BubR1DI expressed on a BubR1–/– background does not show overt increases in misalignments
(Malureanu et al., 2009). This could represent species-specific differences in the reliance of the
KARD for attachment, or on the dependency of BubR1 to recruit PP2A to the kinetochore.
Overexpression of BubR1DN or its complimentary fragment BubR1N does not recapitulate benefits
observed with FL-BubR1 and BubR1DI overexpression. Instead, BubR1DN may be imposing detrimen-
tal effects on the cells, as its overexpression results in a slight increase in aneuploidy and a
decreased ability to sustain a checkpoint arrest in MEFs, though in vivo aneuploidy rates do not
change. Interestingly, however, while the BubR1 N-terminus appears necessary for physiological
benefits, it alone did not exert an anti-tumor effect. FL-Bub1b and Bub1bDI MEFs have increased
BubR1 expression at kinetochores (Figure 2B), corresponding to phenotypic benefits. BubR1N
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cannot localize to kinetochores, in addition to lacking several functional domains such as the putative
kinase/pseudokinase domain, the internal Cdc20-binding domain, and KARD. As we have deter-
mined from the studies herein that the internal binding domain and KARD are dispensable, kineto-
chore localization and subsequent action of BubR1 there might be key to beneficial phenotypes, in
particular, error attachment (Lampson and Kapoor, 2005). This is in agreement with our previous
study in which we found BubR1 that is unable to localize to kinetochores due to disruptions of the
Bub3-binding domain cannot fully rescue spindle assembly checkpoint or mediate complete correc-
tive effects on misalignment in cells depleted of endogenous BubR1 (Malureanu et al., 2009). The
use of transgenic strains in which BubR1N is artificially tethered to kinetochores and evaluating the
impact on SAC and error correction signaling could shed light on this in future studies
(Maldonado and Kapoor, 2011). Other transgenic models could parse out the specific contribution
of kinetochore-localized overexpression to tumor prevention with a domain mutant that does not
permit BubR1 to localize to the kinetochore, as well as overexpression of a kinase-dead BubR1.
Whether or not aneuploidy causes cancer or is simply a feature is a longstanding question
(Giam and Rancati, 2015). Here, we offer a unique perspective by showing the reinforcement of
genomic stability through several complimentary mechanisms, with an emphasis on error correction
machinery, attenuates tumors in a Kras mouse model of lung cancer. Tumor cells often have compro-
mised DNA repair pathways, and are therefore sensitized to chemotherapies such as topoisomerase
inhibitors and alkylating agents that promote cellular damage (Caldero´n-Montan˜o et al., 2014).
There are few, if any, cancer treatments that revolve around promoting chromosomal stability and
reinforcing known checkpoint pathways. Thus, by forcing reliance on the SAC and death in mitosis
by damaging or bypassing other cell-cycle checkpoints, a more potent anti-tumor therapy could be
designed.
Materials and methods
Mouse strains and husbandry
All protocols were reviewed and approved by the Mayo Clinic Institutional Animal Care and Use
Committee. Mice used in these studies were housed in a pathogen-free barrier and are maintained
on a mixed 129SV/E  C57BL/6 genetic background. Full-length Flag-mBub1btransgenic mice have
been described previously (Baker et al., 2013), and the generation of Flag-mBub1bN, Flag-
mBub1bDI, and Flag-mBub1bDN was performed using a similar strategy. The development of con-
structs for these fragments of BubR1 has been described in detail (Malureanu et al., 2009). Tumor
studies of KrasLA1 mice were performed as previously described (Baker et al., 2013). KrasLA1 mice
were obtained from the MMHCC (NCI Frederick) (Johnson et al., 2001). Mice were sacrificed at 6
weeks of age and surface adenomas were counted using a dissection microscope. Formalin-fixed,
paraffin-embedded lung samples were stained for histological analysis using routine haematoxylin
and eosin staining.
Creation of inducible BubR1 deletion mutants
pTripz-Flag-FL-Bub1b was created from pTripz-PKG-puro-loxp (GE Dharmacon, Layfayette, CO). The
loxp sites were removed and a multiple cloning site (MCS) was inserted. Flag-FL-Bub1b was
removed from pMSCV-IRES-GFP (Malureanu et al., 2009) and cloned into the MluI site of the MCS.
Deletion constructs were generated using the Q5 Site-Directed Mutagenesis Kit (New England Biol-
abs, Ipswich, MA; #E0554S) following manufacturer’s instructions from template pTripz-Flag-FL-
Bub1b. The following primers were used to create the following deletion constructs: pTripZ-Flag-
Bub1bDI, Fwd 3’- GACGGGGCAGAAAATGCT-5’, Rev 3’- AAAAATGGAGAAAGGCATACTG-5’;
pTripZ-Flag- Bub1bDKARD, Fwd 3’- TCTGGCTTCTCCAGGTCTT-5’, Rev 3’- GAGGGCCTGGTGA
TGAAC-5’; pTripZ-Flag-Bub1bDPhe, Fwd 3’- TCTCTTTCAGACAAAAAGGAC-5’; Rev 3’- AC
TGGAACCTTTAGAATCAG-5’; pTripZ-Flag-Bub1bDD, Fwd 3’- AAAACTACAGAAGTGGGC-5’, Rev
3’- CTGGGCATTGAGAACCTG-5’; pTripZ-Flag-Bub1bDPheD, Fwd 3’- AAAACTACAGAAGTGGGC-
5’, Rev 3’- CTGGAACCTTTAGAATCAG-5’. We used a similar approach to create pTripZ-Flag-
Bub1bDPheDDKARD using pTripZ-Flag-Bub1bDPheD forward and reverse primers and pTripZ-Flag-
Bub1bDKARD as a template. Cloned plasmids were transfected into HEK-293T cells using the Trans-
Lentiviral shRNA packaging kit with calcium phosphate (GE Dharmacon; #TLP5912) and virus was
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harvested 48 hr post-transfection. Primary wild-type p3 MEFs were infected twice every 8 hr and
selected with 2 mg/ml puromycin (InvivoGen, San Diego, CA) 48 hr post initial infection. At this time,
1 mg/ml doxycycline (Clontech, Mountain View, CA) was added and 48 hr later, cells were processed
for western blotting or monastrol washout, or infected with H2B-RFP for live cell imaging.
In vitro Kras studies
Wild-type MEFs were infected with pBABE-Puro-KRas(G12V) (Addgene plasmid #46746) or empty
vector (Addgene plasmid #1764) and selected with 2 mg/ml puromycin 48 hr post-infection with cells
for live-cell imaging being infected with H2B-RFP at this time. After 48 hr of selection, cells were
processed for western blotting, monastrol washout, or live cell imaging.
Generation and culture of MEFs
Wild-type and Bub1b transgenic MEFs were generated and cultured as described previously
(Baker et al., 2004). At least three independently generated MEF lines per genotype were used
unless otherwise stated. Asynchronous and mitotic shake-off MEF lysates were created as described
previously (Baker et al., 2013).
Western blotting and co-immunoprecipitation
Western blot analysis was performed as previously described (van Ree et al., 2010). Lung tissue
lysates were prepared as previously described (Baker et al., 2013). Briefly, the lung tissue was snap-
frozen in liquid nitrogen and then ground into powder with a mortar and pestle. Ten milligrams of
the powder was resuspended in 100 ml of PBS, boiled for 10 min at 100˚C after the addition of
100 ml Laemmli lysis buffer (Bio-Rad, Hercules, CA), and loaded into Tris-HCl polyacrylamide gels
(Bio-Rad). Primary antibodies used were mouse anti-BubR1 (BD Transduction, San Jose, CA; 612503,
1:1,000), rabbit anti-mouse BubR1 (aa382-420) ([Baker et al., 2004]; 1:1000), rabbit anti-human
BubR1 (aa1-350) ([Baker et al., 2004]; 1:1000), rabbit anti-Flag (Sigma-Aldrich, St. Louis,
MO; F7425, 1:1000), rabbit anti-Flag (Cell Signaling, Danvers, MA; 2368S, 1:1000), rabbit anti-Cdc20
(Santa Cruz, Dallas, TX; sc-8358, 1:1000), mouse anti-Kras (Santa Cruz; sc-30, 1:1000) and rabbit anti-
pCdc20S92 and rabbit anti-pCdc20S153 (generous gifts from Hongtau Yu). All antibodies were
detected with secondary HRP-conjugated goat anti-mouse or anti-rabbit antibodies (Jackson Immu-
noresearch, West Grove, PA; 1:10,000). Ponceau S staining (1% glacial acetic acid, 1.1 g/ml Ponceau
S [Sigma-Aldrich]) served as a loading control for blots. All western data are representative for two
or three independent experiments. Co-IP was performed with mitotic MEFs that were immortalized
by expression of SV40 large T antigen as previously described (Baker et al., 2013). Primary antibod-
ies used were mouse anti-BubR1 (BD Transduction; as above), rabbit anti-mouse BubR1 (aa382-420)
([Baker et al., 2004]; as above), rabbit anti-Cdc20 (Santa Cruz; as above), mouse anti-Mad2 (BD
Transduction, 610679, 1:1000), rabbit anti-Mad2 ([Ricke et al., 2011]; 1:1000). All antibodies were
detected with secondary HRP-conjugated goat anti-mouse or anti-rabbit antibodies (Jackson Immu-
noresearch; as above) except when Cdc20 immunoblot was performed from CDC20 IP, in which
Rabbit TrueBlot Anti-Rabbit IgG HRP (Rockland, Limerick, PA; 18-8816-33 1:1000) was used.
Karyotype analyses
MEF karyotype analyses were performed as previously described on at least n = 3 individual MEF
lines per genotype (Babu et al., 2003). Interphase FISH analysis on single cells isolated from various
fresh tissues from 3-mo-old mice and KrasLA1 hyperplastic lungs was performed as described previ-
ously (Baker et al., 2008), and were analyzed in the Mayo Clinic Cytogenetics Core Facility. At least
100 cells were analyzed per sample. At least n = 3 individual mice per genotype per tissue were
used.
Live-cell imaging experiments
Chromosome segregation analysis was performed on MEFs stably expressing H2B-RFP, as previously
described (Malureanu et al., 2009). In mitotic timing experiments, the time interval between nuclear
envelope breakdown (NEBD) and anaphase onset was measured in H2B-mRFP positive cells by mon-
itoring unchallenged mitoses. Briefly, cells undergoing NEBD were marked and monitored at two
minute intervals until anaphase onset. For SAC sensitivity experiments, cells were treated with
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nocodazole (Sigma-Aldrich) at a final concentration of either 20 or 10 ng/ml and then monitored
from NEBD to anaphase onset. Nocodazole challenge experiments were performed as previously
described (Malureanu et al., 2009). Briefly, nocodazole was added to a final concentration of 100
ng/ml. Cells undergoing NEBD were marked and monitored at 10 min intervals to determine when
they decondensed their chromosomes. The duration of arrest in mitosis, which is defined as the
interval between NEBD (onset of mitosis) and chromatin decondensation (exit from mitosis without
cytokinesis), was then calculated and plotted. For checkpoint silencing and sensitivity experiments,
500 nM or 2 mM AZ3146 (Sigma-Aldrich) was added either concurrently or in sequence with nocoda-
zole. All experiments were performed on at least three independently generated MEF lines unless
stated.
Monastrol washout
Monastrol washout was performed as previously described (Ricke et al., 2012). Briefly 100 mM mon-
astrol (Enzo Life Sciences, Famingdale, NY) was added to cells for 60 min, after which, 10 mM
MG132 (Sigma-Aldrich) was added for 60 min. Cells were then released for 90 min into 10 mM
MG132 alone before fixation (4% PFA for 10 min) and staining with Hoechst. Cells treated with
Aurora B inhibitor were cultured in medium with 10 nM or 50 nM AZD1152-HQPA (ChemieTek, Indi-
anapolis, IN), as specified for each experiment. Cells in which one or more chromosome was mis-
aligned were considered misaligned. All experiments were performed on at least three
independently generated MEF lines unless otherwise stated.
Immunofluorescence
Immunofluorescence was performed and quantified as previously described (Kasper et al., 1999). In
all cases, DNA was visualized with Hoechst and centromeres were visualized with human anti-centro-
meric antibody (Antibodies, Inc, Davis, CA; 15-234-001, 1:100). Primary antibodies used were mouse
anti-BubR1 (BD Transduction; 612503, 1:250), rabbit anti-Flag (Cell Signaling; 2368S, 1:100), rabbit
anti-Mad2 ([Ricke et al., 2011]; 1:500), and mouse-anti-PP2A-B56a (BD Transduction; 610615,
1:200). A laser-scanning microscope (LSM 880; Carl Zeiss) with an inverted microscope (Axiovert
100 M; Carl Zeiss) was used to capture images. For quantification, we used ImageJ software
(National Institutes of Health, Bethesda, MD) as previously described (Ricke et al., 2012). All confo-
cal microscopic images are representative of at least three independent experiments. All experi-
ments were performed on at least three independently generated MEF lines.
Statistical analyses
Prism software (GraphPad Software) was used for all statistical analyses. A two-tailed Mann-Whitney
test was used for pairwise significance analysis in Figure 2C; Figure 9A; Figure 9—figure supple-
ment 1C; Figure 10B. A log-rank Mantel-Cox test was used for significance analysis in Figure 5B;
Figure 9B; Figure 10C. A two-tailed unpaired t -test was used for comparisons in the following fig-
ures: Figure 2D; Figure 3B and D; Figure 4B–D; Figure 5A; Figure 5—figure supplement 1B;
Figure 7B; Tables 1–3. A two-tailed paired t-test was used for significance analysis in Figure 9C. A
Fischer’s exact two-tailed test was used for significance analysis in Figure 10D and E. For consis-
tency in these analyses, significance is indicated as follows: *p<0.05; **p<0.01; and ***p<0.001.
Sample sizes were chosen based on previously published studies where differences were observed.
No samples were excluded.
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